Go or no go? A first for Nefecon
Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.
Prilenia hopes to buck the Huntington’s trend
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
Amgen finally Navigates a win
The asthma project tezepelumab shows an effect in both eosinophilic and non-eosinophilic patients.
Big pharma spinouts grow up
Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.
Amarin falls at obvious hurdle
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
For Lundbeck’s acquisition strategy bad luck comes in threes
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
